Literature DB >> 20155320

Rifaximin and Crohn's disease: a new solution to an old problem?

A S Day, R B Gearry.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20155320     DOI： 10.1007/s10620-010-1140-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  17 in total

1.  Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice.

Authors:  K L Madsen; J S Doyle; M M Tavernini; L D Jewell; R P Rennie; R N Fedorak
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

2.  Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice.

Authors:  K L Madsen; J S Doyle; L D Jewell; M M Tavernini; R N Fedorak
Journal:  Gastroenterology       Date:  1999-05       Impact factor: 22.682

Review 3.  Inflammatory bowel disease: etiology and pathogenesis.

Authors:  C Fiocchi
Journal:  Gastroenterology       Date:  1998-07       Impact factor: 22.682

4.  Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum.

Authors:  G R D'Haens; K Geboes; M Peeters; F Baert; F Penninckx; P Rutgeerts
Journal:  Gastroenterology       Date:  1998-02       Impact factor: 22.682

5.  An open-label evaluation of rifaximin in the treatment of active Crohn's disease.

Authors:  Ira Shafran; Lorin K Johnson
Journal:  Curr Med Res Opin       Date:  2005-08       Impact factor: 2.580

6.  Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease activity.

Authors:  Ira Shafran; Patricia Burgunder
Journal:  Dig Dis Sci       Date:  2010-01-29       Impact factor: 3.199

7.  Use and safety of rifaximin in children with inflammatory bowel disease.

Authors:  Pramodha Muniyappa; Reema Gulati; Franziska Mohr; Vera Hupertz
Journal:  J Pediatr Gastroenterol Nutr       Date:  2009-10       Impact factor: 2.839

8.  Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

Authors:  C Prantera; H Lochs; M Campieri; M L Scribano; G C Sturniolo; F Castiglione; M Cottone
Journal:  Aliment Pharmacol Ther       Date:  2006-04-15       Impact factor: 8.171

Review 9.  Antibiotics and probiotics in inflammatory bowel disease: why, when, and how.

Authors:  Cosimo Prantera; Maria Lia Scribano
Journal:  Curr Opin Gastroenterol       Date:  2009-07       Impact factor: 3.287

10.  Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice.

Authors:  H C Rath; M Schultz; R Freitag; L A Dieleman; F Li; H J Linde; J Schölmerich; R B Sartor
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441
View more
  2 in total

1.  Rifaximin for inflammatory bowel disease.

Authors:  Mario Guslandi
Journal:  Dig Dis Sci       Date:  2010-06       Impact factor: 3.199

2.  Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation.

Authors:  Jie Cheng; Yatrik M Shah; Xiaochao Ma; Xiaoyan Pang; Toshiya Tanaka; Tatsuhiko Kodama; Kristopher W Krausz; Frank J Gonzalez
Journal:  J Pharmacol Exp Ther       Date:  2010-07-13       Impact factor: 4.030
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.